Adjuvant trastuzumab therapy for HER2-positive breast cancer.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 18757259)

Published in Clin Breast Cancer on August 01, 2008


Mohammad Jahanzeb1

Author Affiliations

1: Aptium Oncology, Los Angeles, CA, USA.

Associated clinical trials:

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 | NCT00004067

Trastuzumab in Treating Women With Primary Breast Cancer | NCT00045032